Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK

Journal of Medical Economics

Volumn 14, Issue 3, 2011, Pages 357-366

  Beaudet, Amélie ^a   Palmer, James L ^a   Timlin, Louise ^b   Wilson, Bernard ^c   Bruhn, David ^b   Boye, Kristina S ^b   Lloyd, Adam ^a  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Lilly UK   (United Kingdom)

Author keywords

Cost effectiveness; Diabetes mellitus; Exenatide; Glargine; Type 2

Indexed keywords

EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; LIRAGLUTIDE;

ADULT; ARTICLE; BODY MASS; CONTROLLED DRUG RELEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; STATE MEDICINE; VENOMS;

EID: 79956104536     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.579213     Document Type: Article

References (54)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53 (Pubitemid 38579764)
2. World Health Organization. Diabetes - country and regional data. 2010. Available at: http://www.who.int/diabetes/facts/world-figures/en/
3. Gonzalez EL, Johansson S, Wallander MA, et al. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009;63:332-6
4. Brunner EJ, Mosdol A, Witte DR, et al. Dietary patterns and 15-year risks of major coronary events, diabetes, and mortality. Am J Clin Nutr 2008;87:1414-21 (Pubitemid 351679785)
5. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359:2220-32
6. Perry IJ, Wannamethee SG, Walker MK, et al. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 1995;310:560-4
7. IDF Diabetes Atlas. Economic impact of diabetes. 2010 [Accessed 2010 Mar 23]. Available at: http://www.diabetesatlas.org/content/economicimpacts-diabetes
8. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
9. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
10. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-9 (Pubitemid 32048520)
11. Gulliford MC, Dodhia H, Sivaprasad S, et al. Family practices' achievement of diabetes quality of care targets and risk of screen-detected diabetic retinopathy. PLoS One 2010;5:e10424
12. Leese GP, Boyle P, Feng Z, et al. Screening uptake in a well-established diabetic retinopathy screening program: the role of geographical access and deprivation. Diabetes Care 2008;31:2131-5
13. Exenatide (Byetta) Summary of Product Characteristics. 2010 May 4 [Accessed 2010 July 20]. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000698/WC500051845.pdf
14. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
15. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in significantly greater improvement in glycemic control with less nausea than exenatide twice daily in patients with type 2 diabetes. American Diabetes Association Annual Meeting 2010 Abstract 0008-LB. 2010
16. Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
17. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
18. National Institute for Clinical Excellence. type 2 diabetes: newer agents. May 2009
19. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision- making. Curr Med Res Opin 2004;20(Suppl 1):S5-26 (Pubitemid 39349905)
20. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40 (Pubitemid 39349906)
21. Eli Lilly and company. GWBR Clinical Study Report, 2009 22. National Institute for Clinical Excellence. NICE short clinical guideline 87 - type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. May 2009. Available at http://www.nice.org.uk/cg87
22. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249-58
23. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):136-45 (Pubitemid 26011611)
24. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30 (Pubitemid 40360759)
25. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65 (Pubitemid 47357727)
26. DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy. New York: McGraw-Hill, 2008
27. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
28. Haymarket Medical Media. Monthly Index of Medical Specialties, August 2009. Available at: www.mims.co.uk
29. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence 2008. Available at: http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf
30. Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2010; Mar 12 [Epub ahead of print]
31. Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005
32. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ 2007;335:358-9 (Pubitemid 47359304)
33. Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22 (Pubitemid 46456909)
34. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
35. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
36. National Institute for Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus. Appraisal consultation document. 2010 June 14 [Accessed 2010 July 21]. Available at: http://www.nice.org.uk/guidance/index. jsp?action/article&o/49173
37. Liraglutide (Victoza) Summary of Product Characteristics. 2010 February 22 [Accessed 2010 Jul 21]. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/001026/WC500050017.pdf
38. Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther 2006;28:1989-95 (Pubitemid 46215746)
39. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22:340-9 (Pubitemid 34791321)
40. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
41. Wasserfallen JB, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;19:1594-9 (Pubitemid 38786756)
42. Sharma S, Oliver-Fernandez A, Bakal J, et al. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol 2003;87:259-61 (Pubitemid 36307893)
43. Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24 (Pubitemid 351590891)
44. Hopkins RB, Tarride JE, Bowen J, et al. Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Can J Ophthalmol 2008;43:213-17 (Pubitemid 351518174)
45. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004;30:549-56 (Pubitemid 40070357)
46. Davies R, Wittrup-Jensen KU, Peters JR, et al. The impact on health-related quality of life (EQ-5Dindex) in people with type 1 diabetes who experience severe hypoglycemia. Diabetologia 2005;48(Suppl 1):A292
47. National Institute for Clinical Excellence. Technology appraisal guidance - No. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. December, 2002
48. National Health Service. Prescription Cost Analysis 2008. 2009 April 21. Available at: http://www.ic.nhs.uk/statistics-and-data-collections/primarycare/ prescriptions/prescription-cost-analysis-2008
49. Melville A, Richardson R, McIntosh A, et al. Complications of diabetes: screening for retinopathy and management of foot ulcers. Qual Health Care 2000;9:137-41
50. Personal Social Services Research Unit UK. Unit Costs of Health and Social Care 2008. Canterbury, UK: University of Kent
51. National Health Service. NHS reference costs 2007-08. 2009 August 5. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-098945
52. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442-50 (Pubitemid 36776003)
53. The National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians, 2008
54. Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care 2002;11:70-4